GlassScriptPhysician profile
Danielle Medvinsky
NPI 1306556923
$4,148.75
in general payments reported to CMS, 2019-2025
26 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $48.72 · 2023: $1,169 · 2024: $1,790 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,100.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,742.64 | 2023-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $920.02 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.01 | 2023-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $216.16 | 2023-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $126.75 | 2023-2024 | |
| Amgen INC. | $69.09 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $67.18 | 2023-2025 | Dupixent |
| Axsome Therapeutics, INC. | $66.92 | 2022-2023 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $66.49 | 2023-2024 | Aralast |
| Insmed, INC. | $63.31 | 2024 | Arikayce |
| Genzyme Corporation | $59.60 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $57.77 | 2024 | Lumryz |
| Verona Pharma, INC. | $57.57 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $53.33 | 2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $49.29 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $47.10 | 2023 | Xolair |
| Pfizer INC. | $37.56 | 2025 | |
| Philips North America LLC | $32.11 | 2023-2025 | Vest Therapy Und |
| Ani Pharmaceuticals, INC. | $28.31 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $25.60 | 2024 | Acthar |
| Vifor Pharma, INC. | $23.17 | 2025 | Zemaira |
| Paratek Pharmaceuticals, INC. | $21.57 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $20.05 | 2025 | |
| Viatris Specialty LLC | $14.25 | 2025 | Yupelri |
| Tactile Systems Technology INC | $14.09 | 2025 | Flexitouch Plus, Nimbl |
| Hikma Pharmaceuticals USA | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Medvinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.